iShares NASDAQ Biotechnology Index (NASDAQ:IBB) was upgraded by equities researchers at Vetr from a “hold” rating to a “buy” rating in a report released on Tuesday. The brokerage currently has a $300.66 target price on the financial services provider’s stock. Vetr‘s target price would indicate a potential upside of 4.52% from the stock’s current price. […]
